AstraZeneca Archives - Pharmaphorum

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

https://pharmaphorum.com/news/az-and-msds-lynparza-gets-eu-nod-for-hard-to-treat-breast-cancer/

AZ’s Fasenra also works in rare organ damage diseases

AstraZeneca’s asthma drug Fasenra also works in a group of rare diseases that can lead to potentially fatal

AZ’s Fasenra also works in rare organ damage diseases

https://pharmaphorum.com/news/azs-fasenra-also-works-in-rare-organ-damage-diseases/

AZ signs multi-billion cancer R&D deal with Daiichi Sankyo

AstraZeneca is to raise $3.5 billion to fund a global development and marketing collaboration with Daiichi Sankyo, for

AZ signs multi-billion cancer R&D deal with Daiichi Sankyo

https://pharmaphorum.com/news/az-signs-multi-billion-cancer-rd-deal-with-daiichi-sankyo/

AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancer

AstraZeneca has won the backing of NICE for its cancer immunotherapy Imfinzi for non-small cell lung cancer (NSCLC),

AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancer

https://pharmaphorum.com/news/az-gets-nice-nod-for-big-advance-imfinzi-in-lung-cancer/

HPAPI 2019 Conference – Exclusive Interview Released with AstraZeneca

HPAPI Conference 2019 – AstraZeneca Interview

HPAPI 2019 Conference – Exclusive Interview Released with AstraZeneca

https://pharmaphorum.com/partner-content/hpapi-2019-conference-exclusive-interview-released-with-astrazeneca/

AZ’s diabetes drug Forxiga approved in EU for type 1 disease

AstraZeneca’s diabetes drug Forxiga (dapagliflozin) has been approved in the EU in patients with type 1 disease. Forxiga

AZ’s diabetes drug Forxiga approved in EU for type 1 disease

https://pharmaphorum.com/news/azs-diabetes-drug-forxiga-approved-in-eu/

AZ backs diabetes drug Farxiga with new cardio analysis

AstraZeneca continues to make the case for its Farxiga diabetes drug, highlighting a cardiology analysis that it hopes

AZ backs diabetes drug Farxiga with new cardio analysis

https://pharmaphorum.com/news/az-backs-diabetes-drug-farxiga-with-new-cardio-analysis/

Precision medicine: AZ’s Ruth March on its next steps

AstraZeneca’s senior vice-president and head of precision medicine, research & development, Ruth March, has been central to the

Precision medicine: AZ’s Ruth March on its next steps

https://deep-dive.pharmaphorum.com/magazine/pharma-research-rare-diseases/astrazeneca-ruth-march-precision-medicine/

AZ joins with Seres to research role of gut microbiome in cancer

AstraZeneca has announced an immuno-oncology collaboration with US biotech Seres Therapeutics, which will focus on increasing understanding of

AZ joins with Seres to research role of gut microbiome in cancer

https://pharmaphorum.com/news/az-joins-with-seres-to-research-role-of-gut-microbiome-in-cancer/

Trending

AstraZeneca

Hello World

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

AZ’s Fasenra also works in rare organ damage diseases

AZ signs multi-billion cancer R&D deal with Daiichi Sankyo

AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancer

HPAPI 2019 Conference – Exclusive Interview Released with AstraZeneca

AZ’s diabetes drug Forxiga approved in EU for type 1 disease

AZ backs diabetes drug Farxiga with new cardio analysis

Precision medicine: AZ’s Ruth March on its next steps

AZ joins with Seres to research role of gut microbiome in cancer

Search

Advanced Search

Trending

AstraZeneca

Hello World